港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

英派藥業-B

36.220

-0.760-2.06%

成交量：43.72萬

成交額：1,567.24萬

市值：102.31億

市盈率：-25.14

高：36.600

開：36.600

低：35.060

收：36.980

52周最高：47.980

52周最低：28.200

股本：2.82億

香港流通股本：2.82億

量比：1.36

換手率：0.15%

股息：- -

股息率：- -

每股收益(LYR):-1.441

淨資產收益率：--

總資產收益率：-40.35%

市淨率：-9.26

市盈率(LYR):-25.14

市銷率: 232.00

資料載入中...

總覽公司新聞公告

《大行》高盛列出具有納入南向交易潛力半新股(表)

阿斯达克财经

英派藥業-B：6月10日因超額配股權行使發行629.64萬股H股，涉資約1.27億港元

英派藥業-B(07630)因超額配股權獲行使而發行629.64萬股H股

英派藥業-B(07630)：悉數行使超額配股權、穩定價格行動及穩定價格期結束

英派藥業-B(07630)：超額配股權獲悉數行使

英派藥業-B5月股份變動月報：股本保持穩定

英派藥業－Ｂ(07630)出現大手買入20萬股，成交價$42.04，涉資840.8萬

阿斯达克财经

英派藥業-B授予董事股份購回授權，規模達已發行股本一成

英派藥業-B(07630)：IMP1734於2026年ASCO年會公布I/II期臨床數據

英派藥業－Ｂ(07630)股價大幅上升18.766%，現價港幣$37.34

阿斯达克财经

異動解讀 | 英派藥業-B盤中大漲15.59%，受技術反彈、內部增持及核心產品納入醫保等多重利好推動

異動解讀｜英派藥業-B盤中上漲13.17%，上市初期獲利回吐後快速反彈獲資金回補

異動解讀 | 英派藥業-B盤中大跌5.18%，上市後衝高回落現獲利回吐壓力

異動解讀｜英派藥業-B盤中下跌5.77%，上市後衝高回落或現獲利回吐壓力

英派藥業－Ｂ(07630)股價下跌5.155%，現價港幣$36.8

阿斯达克财经

港股異動 | 英派藥業-B(07630)尾盤漲近4% 核心產品塞納帕利去年12月已納入醫保

英派藥業－Ｂ(07630)股價上升9%，現價港幣$43.6

阿斯达克财经

異動解讀 | 英派藥業-B盤中大漲6.95%，上市表現強勁、核心產品納入醫保及創新管線潛力受關注

【新股IPO】英派藥業(07630)首掛收報41.86港元較招股價高108.26%

港股異動 | 英派藥業-B首日高開高走，股價漲幅擴大至117%

老虎资讯综合

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/07630/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派藥業-B","latestPrice":36.22,"timestamp":1782461289880,"preClose":36.98,"halted":0,"volume":437200,"delay":0,"changeRate":-0.020551649540291997,"floatShares":282461530,"shares":282461530,"eps":-1.440772,"marketStatus":"休市中","change":-0.76,"latestTime":"06-26 16:08:09","open":36.6,"high":36.6,"low":35.06,"amount":15672393,"amplitude":0.041644,"askPrice":36.22,"askSize":7400,"bidPrice":35.66,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.16,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":36.98,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":1.3625031169393553,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.440772,"volumeRatio":1.3625031169393553,"shares":282461530,"dividePrice":0,"high":36.6,"amplitude":0.041644,"preClose":36.98,"low":35.06,"week52Low":28.2,"pbRate":"-9.26","psRate":"232.00","week52High":47.98,"institutionHeld":0,"latestPrice":36.22,"committee":-0.947368,"eps":-1.440772,"divideRate":0,"volume":437200,"delay":0,"ttmEps":-1.16,"open":36.6,"prevYearClose":20.1,"prevWeekClose":37,"prevMonthClose":39.9,"prevQuarterClose":20.1,"fiveDayClose":37,"twentyDayClose":37.18,"sixtyDayClose":20.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-06-26","current":-31.224138,"percent":0.870968,"low":-34.323153,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"high":-16.800385,"avg":-30.174045,"sd":2.897097,"marketCap":10002701008},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008}],"updateTime":1782520399335},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643221934","title":"《大行》高盛列出具有納入南向交易潛力半新股(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643221934","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643221934?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 10:44","pubTimestamp":1781491440,"startTime":"0","endTime":"0","summary":"高盛发表报告，筛选具有纳入南向交易潜力的新上市港股：MiniMax思格能源曦智科技德适生物长光辰芯群核科技深演智能商米科技云迹飞速创新剂泰科技乐动机器人云英谷科技丹诺医药泽景股份瀚天天成华曦达拓璞数控凯乐士科技驭势科技傅里叶首钢朗泽东阳光药天星医疗创想三维天辰生物极视角英派药业华研机器人 爱芯元智瑞博生物HashKey翼菲科技大金重工(港股报价延迟最少十五分钟。沽空资料截至 2026-06-12 16:25。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20251231085225954_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20251231085225954_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1529016/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1529016/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03310","BK1116","02723","BK1147","03277","02526","01779","06938","02553","00068","00600","06872","00901","BK1149","01236","01879","02632","06871","BK1169","06656","06636","00100","BK1144","01081","BK1159","02670","03388","BK1163","BK1179","BK1191","BK1193","BK1161","01609","06810","07630","03887","01021","BK1156","07666","07688","BK1137","03355","BK1100","02726","BK1109","BK1117","02729","06887","01511","03625"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106328124","title":"英派藥業-B：6月10日因超額配股權行使發行629.64萬股H股，涉資約1.27億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106328124","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106328124?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 06:12","pubTimestamp":1781129528,"startTime":"0","endTime":"0","summary":"2026年6月11日，南京英派药业股份有限公司（英派药业-B，股票代码：07630）发布公告，披露于2026年6月10日因超额配股权获悉数行使，新增发行并配发6,296,400股H股，占发行前已发行股本约2.3%。每股发行价为20.1港元，合计涉资约1.27亿港元。\n本次发行完成后，公司已发行股本由276,165,130股增至282,461,530股。公司确认本次发行已遵循香港联交所证券上市规则及相关法律法规规定，并获得董事会正式授权。上述公告由公司执行董事兼首席执行官蔡遂雄签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"英派药业-B：6月10日因超额配股权行使发行629.64万股H股，涉资约1.27亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642471572","title":"英派藥業-B(07630)因超額配股權獲行使而發行629.64萬股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642471572","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642471572?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 06:10","pubTimestamp":1781129453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，于2026年6月10日因超额配股权获悉数行使而发行及配发629.64万股H股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641107217","title":"英派藥業-B(07630)：悉數行使超額配股權、穩定價格行動及穩定價格期結束","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107217","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641107217?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 16:53","pubTimestamp":1780908808,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，有关全球发售的稳定价格期于2026年6月7日(星期日)结束。于稳定价格期，稳定价格操作人并无出于稳定价格的目的在市场上购入或出售任何H股。紧随超额配股权获悉数行使及稳定价格期结束后，本公司将继续遵守上市规则第19A.28B条的公众持股量规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641760148","title":"英派藥業-B(07630)：超額配股權獲悉數行使","url":"https://stock-news.laohu8.com/highlight/detail?id=2641760148","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641760148?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 20:54","pubTimestamp":1780664056,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)公布，招股章程所述超额配股权已于2026年6月5日(星期五)获整体协调人(为其本身及代表国际包销商)悉数行使，涉及合共629.64万股H股，占于任何超额配股权获行使前全球发售项下初步可供认购的发售股份总数约15%。因超额配股权获行使而将予发行的H股(“超额配发股份”)将由本公司按每股H股 20.10港元发行及配发。超额配发股份将用于加快向同意延迟交付其根据全球发售认购的相关H股的承配人交付部分H股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193760729","title":"英派藥業-B5月股份變動月報：股本保持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193760729","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193760729?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 18:11","pubTimestamp":1780567895,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司于2026年6月4日发布截至2026年5月31日止的股份变动月报。公告显示，公司法定/注册股本在报告期内无变化，截至2026年5月31日止的法定/注册股本数为人民币276,165,130元；普通股H股的已发行股本维持在276,165,130股，未发生任何新增发行、回购或转换注销。公司5月内也未发生任何库存股变动，库存股份数仍为0股。根据本次月报，英派药业-B的股本结构自上市以来保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640196158","title":"英派藥業－Ｂ(07630)出現大手買入20萬股，成交價$42.04，涉資840.8萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2640196158","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640196158?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 16:04","pubTimestamp":1780560240,"startTime":"0","endTime":"0","summary":"[大手成交]英派药业－Ｂ(07630)在下午04:04出现大手买入，成交量为20万，成交价为港币$42.04，涉资840.8万。至目前为止，股价跌1.099%，今日最高价为$42.04，而最低价为$38.48，总成交量为79.5万股，总成交金额港币$3.289千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2606047223/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2606047223/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130218577","title":"英派藥業-B授予董事股份購回授權，規模達已發行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1130218577","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130218577?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 18:36","pubTimestamp":1780483018,"startTime":"0","endTime":"0","summary":"英派药业-B6月3日发布公告，董事会已获一般性授权，可在香港联合交易所有限公司按不超过公司已发行H股总数10%的规模进行股份购回。现有发行股本约2.76亿股H股，授权范围最高可达约2761.65万股，购回事宜尚需于2026年6月25日召开的年度股东大会上审议并生效。根据公告，英派药业-B上市后，于2026年5月13日至6月初期间，H股最高价为每股47.98港元，最低为28.20港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981904","title":"英派藥業-B(07630)：IMP1734於2026年ASCO年會公布I/II期臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981904","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640981904?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 08:37","pubTimestamp":1780274251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，于2026年5月29日至6月2日在美国芝加哥举办的2026年美国临床肿瘤学会(ASCO)年会上，以壁报形式发布高选择性PARP1抑制剂IMP1734(亦称为EIK1003)的最新I/II期临床数据。该壁报(摘要编号：#3102)展示了IMP1734单药治疗及联合紫杉醇治疗晚期实体瘤的安全性与初步有效性数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637939195","title":"英派藥業－Ｂ(07630)股價大幅上升18.766%，現價港幣$37.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2637939195","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637939195?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 15:40","pubTimestamp":1779435600,"startTime":"0","endTime":"0","summary":"[上升股]英派药业－Ｂ(07630) 股价在下午03:40比前收市价大幅上升18.766%，现股价为港币$37.34。至目前为止，今日最高价为$37.34，而最低价为$32.0。总成交量为171.139万股，总成交金额为港币$6.07千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605225438/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605225438/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121551346","title":"異動解讀 | 英派藥業-B盤中大漲15.59%，受技術反彈、內部增持及核心產品納入醫保等多重利好推動","url":"https://stock-news.laohu8.com/highlight/detail?id=1121551346","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121551346?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 11:15","pubTimestamp":1779419700,"startTime":"0","endTime":"0","summary":"英派药业-B今日盘中大涨15.59%，引起了市场的广泛关注。消息面上，此次上涨可能受到多重因素驱动。其次，公司关联方在上市日进行了大额增持，释放了内部对公司前景的信心信号。更重要的是，公司的核心产品塞纳帕利已被纳入国家医保目录并从今年开始执行医保价格，这有望显著推动其营收放量。英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的生物技术公司，目前已进入商业化阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103271327","title":"異動解讀｜英派藥業-B盤中上漲13.17%，上市初期獲利回吐後快速反彈獲資金回補","url":"https://stock-news.laohu8.com/highlight/detail?id=1103271327","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103271327?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 11:13","pubTimestamp":1779419602,"startTime":"0","endTime":"0","summary":"5月22日，英派药业-B盘中上涨13.17%，报35.58港元，成交额871.6万港元。消息面上，公司于5月13日以每股20.10港元登陆港交所，首日大涨108.26%，此后经历获利回吐股价自高点回落超15%，昨日一度下跌逾5%后今日迎来强势反弹。英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的商业化阶段生物技术公司，核心产品塞纳帕利已在中国获批上市，产品管线涵盖PARP1/2、PARP1、ATR、WEE1等多个靶点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161371010","title":"異動解讀 | 英派藥業-B盤中大跌5.18%，上市後衝高回落現獲利回吐壓力","url":"https://stock-news.laohu8.com/highlight/detail?id=1161371010","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161371010?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 10:31","pubTimestamp":1779330713,"startTime":"0","endTime":"0","summary":"英派药业-B(07630)今日盘中股价大幅下挫5.18%，引发市场关注。消息面上，公司近期登陆港交所后股价经历了大幅上涨，自高点回落幅度已超过15%，短期获利盘兑现压力开始显现。此外，公司目前仍处于亏损阶段，2025年净亏损约2.96亿元，而营收仅为3825万元，尚无法覆盖高强度的研发投入，基本面对当前较高估值的支撑力度有限，可能也是股价承压的因素之一。英派药业是一家基于合成致死机制的精准抗癌疗法企业，其核心产品塞纳帕利已在中国获批上市并纳入医保目录。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118559761","title":"異動解讀｜英派藥業-B盤中下跌5.77%，上市後衝高回落或現獲利回吐壓力","url":"https://stock-news.laohu8.com/highlight/detail?id=1118559761","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118559761?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 10:30","pubTimestamp":1779330603,"startTime":"0","endTime":"0","summary":"5月21日，英派药业-B盘中下跌5.77%，报35.28港元，成交额511.1万港元。消息面上，公司于5月13日以每股20.10港元定价登陆港交所，首日收报41.86港元，较招股价涨108.26%，此后连续多日维持高位震荡。经历上市后大幅上涨，股价自高点回落幅度已超15%，短期获利盘兑现压力显现。值得关注的是，公司仍处亏损阶段，2025年净亏损约2.96亿元，营收仅3825万元，尚无法覆盖高强度研发投入，基本面对高估值的支撑力度有限。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636155228","title":"英派藥業－Ｂ(07630)股價下跌5.155%，現價港幣$36.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2636155228","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636155228?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 14:10","pubTimestamp":1779257400,"startTime":"0","endTime":"0","summary":"[下跌股]英派药业－Ｂ(07630) 股价在下午02:10比前收市价下跌5.155%，现股价为港币$36.8。至目前为止，今日最高价为$39.8，而最低价为$36.8。总成交量为36.18万股，总成交金额为港币$1.381千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605202804/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605202804/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636835929","title":"港股異動 | 英派藥業-B(07630)尾盤漲近4% 核心產品塞納帕利去年12月已納入醫保","url":"https://stock-news.laohu8.com/highlight/detail?id=2636835929","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636835929?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 15:49","pubTimestamp":1779176941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B尾盘涨近4%，截至发稿，涨3.93%，报39.66港元，成交额1382.25万港元。国投证券国际指出，英派药业为国内合成致死赛道的制药企业，已与Eikon、华东医药达成战略合作，核心产品塞纳帕利已纳入医保，短期可关注其医保放量和EMA上市申请审批进度，长期看其他管线临床数据读出及商业化进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","07630","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635388775","title":"英派藥業－Ｂ(07630)股價上升9%，現價港幣$43.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2635388775","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635388775?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 09:45","pubTimestamp":1778809500,"startTime":"0","endTime":"0","summary":"[上升股]英派药业－Ｂ(07630) 股价在上午09:45比前收市价上升9%，现股价为港币$43.6。至目前为止，今日最高价为$43.6，而最低价为$38.98。总成交量为13.1万股，总成交金额为港币$549.918万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260515710/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260515710/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145155707","title":"異動解讀 | 英派藥業-B盤中大漲6.95%，上市表現強勁、核心產品納入醫保及創新管線潛力受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1145155707","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145155707?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 09:41","pubTimestamp":1778809313,"startTime":"0","endTime":"0","summary":"英派药业-B今日盘中大涨6.95%，引起了市场的广泛关注。消息面上，公司于5月13日以每股20.10港元定价登陆港交所，香港公开发售获2282.4倍超额认购，一手中签率仅1.5%，首日收报41.86港元，较招股价涨108.26%，上市后市场情绪延续强势。此外，公司核心产品塞纳帕利已于2025年1月获批用于卵巢癌一线维持治疗，并于2025年12月纳入国家医保目录，自今年1月起正式执行医保价格，有望推动营收持续放量。公司在研管线IMP32为全球首个靶向CEACAM5的双载荷ADC，具备First-in-Class地位，展示了公司的研发实力和未来增长潜力，进一步增强了投资者信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635201905","title":"【新股IPO】英派藥業(07630)首掛收報41.86港元 較招股價高108.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635201905","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635201905?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 16:16","pubTimestamp":1778660200,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英派药业(07630)首挂收报41.86港元，较招股价高108.26%，全日成交1513.5万股，成交额5.44亿港元，不计手续费，每手200股，账面赚4352港元。该股早盘开报35.5港元，较招股价高76.62%，全日最低33.1港元，最高见45.8港元。最新总市值115.6亿港元。","market":"sh","thumbnail":"https://static.szfiu.com/news/20220324/YjI0MWRiZGM3ZjA2MTU3MTE2NDgwOTA4MzEyNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YjI0MWRiZGM3ZjA2MTU3MTE2NDgwOTA4MzEyNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","SPCX","07630","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198038909","title":"港股異動 | 英派藥業-B首日高開高走，股價漲幅擴大至117%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198038909","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198038909?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 12:00","pubTimestamp":1778644826,"startTime":"0","endTime":"0","summary":"5月13日，$英派药业-B$首日高开高走，截止发稿股价涨超117%。核心产品派舒宁已于2025年1月获得中国国家药品监督管理局批准上市，并于2025年12月纳入国家基本医保目录。此外，英派的IMP32是全球首个、且目前唯一靶向CEACAM5的TOP1i+ATRi双载荷ADC，具备明确的First-in-Class地位。随着塞纳帕利自 2026 年1月1日起正式执行国家医保目录价格，叠加公司在研管线持续推进、有望持续兑现更多里程碑收益，有望实现营收规模持续快速放量增长。","market":"hk","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}